Deze week: ortheses (brace of spalk) voor hallux valgus (voetknobbel ... “Op de website van Epitact, een bekend merk, tonen ze beelden van de situatie met en zonder orthese.

(Reuters) -Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Merck recently announced a third-quarter dividend affirmation of $0.81 per share, underscoring its commitment to returning value to shareholders. Over the past week, the company's stock remained ...

Financial giants have made a conspicuous bullish move on Merck & Co. Our analysis of options history for Merck & Co MRK revealed 30 unusual trades. Delving into the details, we found 60% of ...

Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely ...

Merck trades at a historically low valuation with a 4.2% dividend yield, but faces major headwinds from KEYTRUDA's looming LOE and political risks. The company is highly dependent on KEYTRUDA but ...

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in ...

70. CHICAGO — Amid ongoing uncertainty around funding for the National Institutes of Health, and what it could mean for U.S. innovation, a top Merck executive stressed that the agency is “an ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

Verkade-directeur Dennis Teeken is dringend op zoek naar mensen die in ploegendienst willen komen werken aan één van de zestig meter lange koekjesovens of bij een inpakmachine. Hij denkt dat ze ...

Merck & Co., Inc. (NYSE:MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal valued at over $3 billion, aiming to strengthen its drug pipeline. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...